Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective.

Détails

ID Serval
serval:BIB_9DDA93EC1048
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective.
Périodique
Journal of Medical Economics
Auteur(s)
Wasserfallen J.B., Krieg M.A., Greiner R.A., Lamy O.
ISSN
1369-6998
Statut éditorial
Publié
Date de publication
2008
Volume
11
Numéro
3
Pages
499-523
Langue
anglais
Résumé
OBJECTIVES: To assess the incremental cost-effectiveness ratio (ICER) and incremental cost-utility ratio (ICUR) of risedronate compared to no intervention in postmenopausal osteoporotic women in a Swiss perspective. METHODS: A previously validated Markov model was populated with epidemiological and cost data specific to Switzerland and published utility values, and run on a population of 1,000 women of 70 years with established osteoporosis and previous vertebral fracture, treated over 5 years with risedronate 35 mg weekly or no intervention (base case), and five cohorts (according to age at therapy start) with eight risk factor distributions and three lengths of residual effects. RESULTS: In the base case population, the ICER of averting a hip fracture and the ICUR per quality-adjusted life year gained were both dominant. In the presence of a previous vertebral fracture, the ICUR was below euro45,000 (pound30,000) in all the scenarios. For all osteoporotic women>or=70 years of age with at least one risk factor, the ICUR was below euro45,000 or the intervention may even be cost saving. Age at the start of therapy and the fracture risk profile had a significant impact on results. CONCLUSION: Assuming a 2-year residual effect, that ICUR of risedronate in women with postmenopausal osteoporosis is below accepted thresholds from the age of 65 and even cost saving above the age of 70 with at least one risk factor.
Mots-clé
Age Factors, Aged, Aged, 80 and over, Bone Density Conservation Agents/economics, Bone Density Conservation Agents/therapeutic use, Cost-Benefit Analysis, Etidronic Acid/analogs & derivatives, Etidronic Acid/economics, Female, Hip Fractures/economics, Hip Fractures/prevention & control, Humans, Markov Chains, Medication Adherence, Middle Aged, Osteoporosis, Postmenopausal/complications, Osteoporosis, Postmenopausal/drug therapy, Quality-Adjusted Life Years, Risk Assessment, Sensitivity and Specificity, Spinal Fractures/drug therapy, Spinal Fractures/etiology, Switzerland
Pubmed
Création de la notice
27/06/2009 14:07
Dernière modification de la notice
20/08/2019 15:04
Données d'usage